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Abstract
The Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium was established to
determine the host and virus factors associated with HIV transmission, infection and containment
of virus replication, with the goal of advancing the development of an HIV protective vaccine.
Studies to meet this goal required the use of cryopreserved Peripheral Blood Mononuclear Cell
(PBMC) specimens, and therefore it was imperative that a quality assurance (QA) oversight
program be developed to monitor PBMC samples obtained from study participants at multiple
international sites. Nine site-affiliated laboratories in Africa and the USA collected and processed
PBMCs, and cryopreserved PBMC were shipped to CHAVI repositories in Africa and the USA
© 2014 Elsevier B.V. All rights reserved.
*Corresponding author: Duke University Medical Center, 2812 Erwin Rd., Suite 301, Erwin Terrace II, Durham, NC 27705 USA. Tel.:
+1 919 684-6373; fax: +1 919 681-7766, marcella.sarzottikelsoe@dm.duke.edu.
#Both first authors
1Current address: Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town,
Faculty of Health Sciences, Cape Town, South Africa
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Immunol Methods. Author manuscript; available in PMC 2015 July 01.
Published in final edited form as:






















for long-term storage. A three-stage program was designed, based on Good Clinical Laboratory
Practices (GCLP), to monitor PBMC integrity at each step of this process. The first stage
evaluated the integrity of fresh PBMCs for initial viability, overall yield, and processing time at
the site-affiliated laboratories (Stage 1); for the second stage, the repositories determined post-
thaw viability and cell recovery of cryopreserved PBMC, received from the site-affiliated
laboratories (Stage 2); the third stage assessed the long-term specimen storage at each repository
(Stage 3). Overall, the CHAVI PBMC QA oversight program results highlight the relative
importance of each of these stages to the ultimate goal of preserving specimen integrity from
peripheral blood collection to long-term repository storage.
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1.0 Introduction
The Center for HIV/AIDS Vaccine Immunology (CHAVI) sought to use peripheral blood
mononuclear cell (PBMC) specimens obtained from study participants enrolled at multiple
international sites to determine host immune responses during acute HIV-1-infection and to
identify determinants of host resistance to HIV-1-infection. PBMC were isolated and
cryopreserved at nine international site-affiliated laboratories and shipped to the repositories
for long-term storage and subsequent distribution to CHAVI specialized laboratories (i.e.,
end users). The need for high quality PBMC necessitated the development of a quality
assurance (QA) program to monitor the quality of PBMC isolated and stored.
Here, we describe a comprehensive, Good Clinical Laboratory Practices- (GCLP) compliant
CHAVI QA oversight program designed to monitor initial PBMC integrity upon isolation at
the site-affiliated laboratories and post-thaw viability and recovery of cryopreserved PBMC
at the repositories. This program also assessed the integrity of PBMC held in long-term
storage at the repositories. Acceptance criteria were pre-established for key quality
indicators, and corrective actions were implemented in the event of QC failure. The program
included site remediation to improve the quality of the cryopreserved PBMC.
In developing the program, multiple criteria were monitored to ensure reliable results in
functional and phenotypic assays when the PBMC were thawed at endpoint laboratories.
Quality control (QC) indicators of initial PBMC integrity include viability, PBMC yield/mL
of whole blood, and the time elapsed between blood collection and cryopreservation (Bull et
al., 2007; Dyer et al., 2007; Kierstead et al., 2007; Olemukan et al., 2010). Previous studies
have highlighted the importance of obtaining post-thaw PBMC viabilities of ≥70% since the
results of functional and phenotypic studies are strictly dependent on the viability of the
cryopreserved PBMC (Cox et al., 2005; Kreher et al., 2003; Reimann et al., 2000; Sleasman
et al., 1997; Weinberg et al., 2000; Weinberg et al., 2009; Weinberg et al., 2010). It is also
essential that adequate numbers of cells are recovered from the freezing process to perform
most PBMC functional assays. Therefore, the dual parameters of post-thaw viability and
recovery of cryopreserved PBMC must be monitored (Aziz et al., 2013; Weinberg et al.,
2007). Additional studies also indicated the importance of cryopreserving PBMC within
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eight hours of blood collection since longer processing times adversely affect the
performance of T cells in immunological assays (Bull et al., 2007).
2.0 Materials and Methods
2.1 Study Participants
The CHAVI prospective, observational Clinical Study Protocols were reviewed and
approved by the Institutional Review Board of Duke University Medical Center and by the
responsible Institutional Review Boards or Ethical Committees in the USA, Malawi, South
Africa, Tanzania, and Uganda. All study participants provided written informed consent for
the collection, testing and subsequent analysis of the study samples.
The longitudinal multicenter CHAVI studies enrolled participants that were HIV-infected
[acutely- (n = 376), chronically- (n = 420), undefined (n = 184)] and uninfected [with
autoimmune disease (n = 322) or without (n = 348)], on multiple visits.
Site-affiliated laboratories were established at the Aaron Diamond AIDS Research Center,
New York, New York, USA; the Aurum Institute for Health Research, Klerksdorp, South
Africa; the Centre for the AIDS Programme of Research in South Africa, University of
KwaZulu-Natal, Durban, South Africa; Clinical Laboratory Services, National Health
Laboratory Service/Wits Health Consortium of the University of the Witwatersrand,
Johannesburg, South Africa; Duke University, Durham, North Carolina, USA; the Johns
Hopkins University Research Project (JHUR Project), Malawi College of Medicine,
Blantyre, Malawi; the Kilimanjaro Christian Medical Centre, Moshi, Tanzania; the Medical
Research Council Programme on AIDS/Uganda Virus Research Institute, Entebbe, Uganda;
and the University of North Carolina Project – Malawi (UNC Project), Lilongwe, Malawi.
Two CHAVI central repositories were established at the National Institute of Communicable
Diseases in Johannesburg South Africa (repository 1), and at the University of North
Carolina (UNC) in Chapel Hill, North Carolina, USA (repository 2), for long-term storage
of PBMC specimens shipped from the site-affiliated laboratories. In order to avoid
unnecessary shipments, a CHAVI repository was also established at Duke University,
Durham, NC, USA (repository 3) for long-term storage of PBMC specimens prepared by the
Duke University site-affiliated laboratory.
2.2 PBMC QA Program
The CHAVI QA oversight program was designed to monitor PBMC integrity at three stages
of PBMC isolation and storage (Figure 1).
2.2.1 Stage 1 - PBMC Initial viability, yield, and processing time at the site-
affiliated laboratories
Training: To standardize PBMC isolation and cryopreservation, each site-affiliated
laboratory operated in compliance with required standards for GCLP (Ezzelle et al., 2008;
Sarzotti-Kelsoe et al., 2009; Stiles et al., 2003). Operators used identical CHAVI central
standard operating procedures (SOPs) for the processing, labeling, transport and storage of
PBMC specimens. Staff from the site-affiliated laboratories participated in wet-laboratory
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training provided by the CHAVI repositories. Each trainee had to successfully participate in
a PBMC processing qualification run before processing study participant PBMCs for
CHAVI, and competency was assessed annually thereafter. The CHAVI Central Quality
Assurance Unit, located at Duke University, assessed the overall GCLP compliance of the
program, by monitoring that all processes were planned, performed, monitored, recorded,
and reported in a reliable and consistent manner. The site-affiliated laboratories and the
repositories were audited annually by the sponsor or the CHAVI Central Quality Assurance
Unit for adherence to GCLP standards.
PBMC Processing: Blood was collected into acid-citrate-dextrose anticoagulant blood
collection tubes and transported to each site-affiliated laboratory at room temperature.
PBMC were isolated from blood, following CHAVI Central SOPs, by centrifugation at 800
x g for 30 minutes at room temperature, through Ficoll-paque Plus (GE Healthcare Life
Sciences, Pittsburgh, PA) using Leucosep (Greiner Bio-One, North America, Monroe, NC)
or Accuspin (Sigma-Aldrich, St. Louis, MO) tubes. The PBMC layer was harvested and
washed three times with Hanks Balanced Salt Solution. PBMC were cryopreserved at a
concentration of ≈1 x107 cells/mL in cryopreservation solution (90% fetal bovine serum
(FBS), 10% dimethyl sulfoxide), using cell freezing containers (e.g., “Mr. Frosty” Nalgene
Labware; StrataCooler, Stratagene; or CoolCell, BioCision, LLC) to control the rate of
freezing overnight in a −70/80°C freezer. Although PBMC storage at −70°C for up to three
weeks does not affect recovery and/or viability upon thawing (Disis et al., 2006; Bull et al.
2007), the site-affiliated laboratories were required by SOP, to transfer cryopreserved cells
on the next working day (within 72 hrs.) from −70°C to storage in liquid nitrogen vapor at ≤
−140°. This process was performed to minimize risk and preserve specimen integrity.
Cryopreserved PBMC specimens were temporarily stored in liquid nitrogen freezers at the
site-affiliated laboratories and were subsequently shipped by cryoshipper to repositories 1
and 2 for long-term storage in vapor phase liquid nitrogen. At later dates, PBMV samples
were shipped to CHAVI end users for specialized functional testing. Only PBMC isolated at
the Duke University site-affiliated laboratory were stored on-site at repository 3.
Three quality control (QC) indicators were recorded and monitored for each PBMC
specimen processed by the site-affiliated laboratories: the percentage of viable PBMCs at
the time of isolation (initial viability); the number of PBMC isolated per mL of blood
(yield); the time elapsed between blood collection and initiation of cryopreservation
(processing time). These three parameters had to meet established acceptance criteria.
Acceptance criteria for PBMC initial viability, yield, and processing time results, established
by the HIV Vaccine Trials Network (HVTN) (0.8–3.2 x 106 PBMC/mL blood) (Ducar et al.,
2014) and by other groups (Afonso et al., 2010) were initially used and adjusted over a pilot
study, to the CHAVI population. The CHAVI acceptance criteria, used in all of the studies
described in this manuscript, for PBMC percent viability after isolation were established as
≥95% and for the PBMC yield as 0.7 –3.0 x 106 PBMC/mL blood. The processing time
acceptance criteria were set at ≤8 hours based upon previous studies (Bull et al., 2007,
Kierstead et al., 2007). Once a site-affiliated laboratory was activated to participate in
CHAVI PBMC processing, PBMC viability, yield, and PBMC processing time were
monitored on monthly trend-lines by the manager of the CHAVI central repository 1. For
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values outside the pre-set acceptance criteria, the repository manager worked with the site-
affiliated laboratories to identify the sources and magnitude of the difficulties and to develop
a corrective action plan, including retraining by the repositories and site visits where
necessary.
PBMC shipment from the site-affiliated laboratories to the repositories: Approximately
half of the cryovials from each PBMC donor were shipped separately by the site-affiliated
laboratories to each central repository (repository 1 and 2) to reduce the risk of loss due to
shipment, equipment, or facility failures. The cryovials were shipped in MVE IATA
approved cryoshippers (Chart Biomedical Division, Chart Industries, Inc., Ball Ground, GA)
to maintain the cells at ≤−150°C (Smith et al.; 2007; Weinberg et al, 2010). Cryoshippers
were equipped with continuously recording temperature dataloggers. QC procedures verified
the integrity of the cryoshippers prior to each shipment. PBMC were stored at the CHAVI
repositories in vapor phase liquid nitrogen freezers at ≤−140°C. A CHAVI standardization
study indicated that, after removal from liquid nitrogen vapor, cryopreserved specimens
warmed within 15 seconds to the critical cryogenic temperature of −130°C. Thus, a central
CHAVI SOPs was developed and mandated that all cryopreserved PBMC be handled in a
liquid nitrogen-vapor environment using temperature-monitored transfer pans or CryoCarts
(Chart Industries, Inc.). Specimens were tracked by linking NIAID/DAIDS Laboratory Data
Management System (LDMS) units (provided by Frontier Science and Technology Research
Foundation) to the central database, Atlas (managed by the Statistical Center for HIV/AIDS
Research and Prevention). Each study participant had a unique Participant Identification
Number (PTID), and each specimen aliquot had a unique global specimen identification
number that was linked to the participant and visit.
2.2.2 Stage 2 - Cryopreserved PBMC viability and cell recovery after thawing
at the repositories—To assess the integrity of the PBMC after cryopreservation,
handling and shipment to the repositories, PBMC from each site-affiliated laboratory were
sampled by the CHAVI specimen manager and analyzed quarterly by the central repositories
for post-thaw viability and total cell recovery. HIV-seronegative specimens were primarily
selected and thawed for QC assessment; PBMC specimens isolated from chronically HIV-
infected participants were selected if no HIV-negative specimens were available. If possible,
at least two PBMC specimen vials were selected quarterly for QC assessment. No PBMC
preparations were thawed for assessment from two of the nine site-affiliated laboratories
since no eligible study participants were enrolled.
PBMC thawing: PBMC were rapidly thawed, following a CHAVI central SOP, in a 37°C
water bath and slowly diluted with an equivalent volume of pre-warmed (37°C) (Disis et al.,
2006; Ramachandran et al., 2012) complete medium (RPMI 1640, 10% FBS and antibiotics)
plus 50 Units/mL Benzonase® Nuclease (Novagen, EMD Millipore Division, Merck KGaA,
Darmstadt, Germany) (Smith et al., 2001). Cell counts and percent viability were determined
on the day of the thaw (Day 0) and after overnight rest (Day 1) in complete medium. The
percentage of viable cells on Day 0 and Day 1 were combined for analysis and were
reported as post-thaw viability. The Day 1 post-thaw total cell recovery and viability results
are reported here, since immunogenicity assays using viable PBMC assays are commonly
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performed after overnight rest (Kierstead et al., 2007). Cell counts and viability were
determined with a hemacytometer, a Vi-Cell instrument (Beckman Coulter) using trypan
blue exclusion, or by a Guava Personal Cell Analysis (PCA) instrument (Millipore
Technologies), using Guava ViaCount reagent. Instruments were qualified by comparison
with hemacytometer counts. Since a set of experiments performed by the central repository
2, comparing Vi-Cell and hemacytometer counts indicated that red blood cells (RBCs)
contributed to the Vi-Cell counts, RBCs were lysed using Versalyse (Beckman Coulter)
prior to counting PBMC on the Vi-Cell.
Total cell recovery was calculated as the total cells recovered after thaw divided by the
original vial cell content, x 100. Total cell recovery was used as one QC indicator to monitor
the number of PBMCs that the site-affiliated laboratories actually dispensed in the vial at
cryopreservation. Viability for each cryovial was determined as well upon thawing, but
analyzed as a separate QC value. Both QC measures, total cell recovery and the fraction of
viable cells after thaw, are necessary to effectively evaluate site performance. Based on post-
thaw viability and total cell recovery results initially established from PBMC thawed for
ELISpot analysis (Dr. Ferrari, personal communication), the acceptance criteria for post-
thaw viability was defined as ≥80%, and for the post-thaw total cell recovery was defined as
55–120%. If a QC result did not meet the preset acceptance criteria, the sample was
recounted to verify the results. If the out of criteria result was obtained with an automated
cell-counting instrument, the recount was performed using a hemacytometer and trypan
blue. Inter-operator hemacytometer counting comparisons were performed quarterly, and
repository operators were assessed annually for control sample thawing competency.
2.2.2 Stage 3 – Sentinel Program for long-term storage of cryopreserved
PBMCs at the repositories—Stage 3 of the PBMC QA Program was designed to
monitor the long-term storage of cryopreserved PBMC at the CHAVI repositories. To this
end, a sentinel program was designed using a large number of identical cryovials (control
samples), containing cryopreserved PBMC at a concentration of ≈1 x 107 cells/mL from a
single, HIV-negative leukapheresis participant (see Garcia et al. in this issue), prepared by
the Immunology Quality Assessment Center (IQAC). These sentinel control samples were
shipped to all repositories for storage in each liquid nitrogen freezer containing CHAVI
cryopreserved PBMCs. In these freezers, the sentinel control samples were exposed to the
same storage conditions and potential temperature excursions as the CHAVI cryopreserved
PBMCs. Each quarter, all repositories thawed three control sample vials from each
freezer(s) and determined the post-thaw percent viability and total cell recovery. As an
independent third party verification, all repositories sent three additional control sample
vials by cryoshipper to the IQAC each quarter for assessment. The acceptance criteria for
post-thaw control sample viability and total cell recovery were set during the first quarter
when the three repositories and the IQAC each thawed six control sample vials. The
consensus mean and SD were used to set acceptance criteria specific for the single control
sample batch used during the entire QC cycle; acceptable post-thaw viability was defined as
≥92.9% and post-thaw recovery for the control samples as 57.7 – 120.7%. If individual
control samples QC values were outside the acceptance criteria, the repository or IQAC
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manager initiated investigative/corrective action steps to ensure that cell-counting
procedures were accurate and that the PBMC integrity was maintained.
2.3 Statistical analysis
Statistical comparisons were made using regression and mixed effects models in SAS
Version 9.2. These models were run using PROC MIXED to perform equivalence tests,
using a simple 1 – α confidence interval, based on the population means. An example of the
null hypothesis based on Stage 1 is that the absolute value of the site-affiliated laboratory
mean minus the consensus mean is greater than the equivalence margin. The alternative
hypothesis is that the absolute value of the site-affiliated laboratory mean minus the
consensus mean is less than or equal to the equivalence margin. The alpha level for all tests
was set at 0.05, and a significant p-value (<0.05) indicates that the null hypothesis is rejected
and equivalence (based on the equivalence margin) can be claimed. No adjustment to the
significance level was made for these analyses. The equivalence margins are as follows: for
initial and post-thaw viability, it is 5 percentage points; for PBMC yield, it is 0.5 x 106
cells/mL blood; for PBMC processing time, it is 2 hours; and for post-thaw recovery, it is
15%. The Stage 1 analysis compared each site-affiliated laboratory’s difference from the
consensus mean, as well as pairwise HIV-infection cohort comparisons. Stage 2
comparisons were based on group determinations based on non-overlapping 95% confidence
intervals (CI) of the mean post-thaw QC values for each site-affiliated laboratory. These
comparisons were made with estimates from mixed effects models. Stage 3 comparisons
were made using a regression model.
3.0 Results
3.1 Stage 1– PBMC Initial viability, yield, and processing time at the site-affiliated
laboratories
Data were collected from the nine site-affiliated laboratories processing CHAVI PBMC
specimens over five years. We analyzed PBMC values from CHAVI cohorts of acutely
HIV-infected (n = 1125), chronically HIV-infected (n = 626) and HIV-negative (n = 297)
participants and found that initial PBMC viabilities, yield, and processing time were
equivalent (all p-values <0.001; data not shown) for all cohorts. Thus, the results in Table 1
are derived from combined data from HIV-positive and HIV-negative participants (n =
8,554). As shown in Table 1, the mean PBMC initial viability, yield, and processing time for
all site-affiliated laboratories were within acceptance criteria.
Statistical comparisons were performed using mixed effects models in order to determine
whether sites were equivalent to the consensus mean. The model-based mean viabilities at
all site-affiliated laboratories were found equivalent to the consensus mean (all p-values
<0.001). For PBMC yield, the model-based mean for 8/9 site-affiliated laboratories was
equivalent to the consensus mean (p-value = 0.857, otherwise all p-values <0.007), and the
processing times at 8/9 site-affiliated laboratories were equivalent to the consensus mean (p-
value = 0.656, otherwise all p-values <0.02). The higher PBMC yields observed at one site
decreased after the site began to verify any out of criteria yield results obtained with the Vi-
Cell automated counter, by using hemacytometer counts. Another site’s processing time was
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consistently lower than the consensus mean value, which had no biological consequence on
the PBMC specimen integrity as all sites were within the acceptance criteria of less than 8
hours.
3.2 Stage 2 - Cryopreserved PBMC viability and cell recovery after thawing at the
repositories
The three repositories evaluated the post-thaw viability and recovery of selected
cryopreserved PBMC from the site-affiliated laboratories. The post-thaw PBMC QC data
collected from the seven site-affiliated laboratories over five years from 252 PBMC isolates
are presented in Figure 2. Sixty-nine percent of the thawed PBMC specimens passed the
post-thaw PBMC viability acceptance criteria (mean viability +/− SD: 80.1+/− 20.3%). As
shown in Figure 2A, the mean post-thaw PBMC viability was within the acceptance criteria
at four of the seven site-affiliated laboratories. Statistical comparisons, based on non-
overlapping model-based 95% CI of the mean post-thaw viability for each site-affiliated
laboratory, indicated that site-affiliated laboratories 5, 6, and 7 differed from the other site-
affiliated laboratories. These three site-affiliated laboratories exhibited mean post-thaw
PBMC viability values that were below the acceptance criteria (76.5, 63.6, and 61.2%,
respectively).
With respect to the PBMC recovery QC results, 72.6% of the thawed PBMC isolates passed
the acceptance criteria (mean +/− SD: 77.2% +/− 35.1%). As shown in Figure 2B, the mean
PBMC recovery was within the acceptance criteria at each site-affiliated laboratory. The
percentage of PBMC preparations that failed due to recoveries of >120% decreased during
the PBMC QA period, suggesting that counting errors and/or errors in seeding high numbers
of cells/vial were more prevalent during the early period (data not shown).
In order to determine if the key post-thaw QC indicators for the PBMC isolated by the site-
affiliated laboratories improved during the span of the PBMC QA Program, the quarterly
mean post-thaw QC results obtained from PBMC isolated at each site-affiliated laboratory
over time was examined (data not shown). Site-affiliated laboratories 6 and 7 had post-thaw
viability values that were consistently below the acceptance criteria, although the viability
appeared to improve over time.
The quarterly mean post-thaw PBMC total cell recovery results were within the acceptance
criteria at each site-affiliated laboratory.
3.3 Stage 3 – Sentinel Program for long-term storage of cryopreserved PBMCs at the
repositories
Stage 3 of the PBMC QA oversight program was designed to monitor the long-term storage
of cryopreserved PBMC at the CHAVI repositories, by assessing post-thaw viability and
recovery of identical sentinel control samples stored in each liquid nitrogen freezer
containing CHAVI cryopreserved PBMCs.
Two years of control sample thawing QC data (n=406) from the three CHAVI repositories
and the IQAC were analyzed statistically for comparisons between Day 0 and Day 1 mean
post-thaw viability and total cell recovery results. There was no evidence that the Day 0 and
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Day 1 control sample viabilities were not equivalent (p<0.001). Therefore, these results were
combined for analysis. However, the Day 0 and Day 1 model-based mean control sample
recoveries were not equivalent (p=0.519), with a lower recovery on Day 1. Therefore, the
results for Day 1 are reported as PBMC would typically be rested for a day prior to assay
use. In addition, the mean control sample post-thaw viability and recovery data were
analyzed statistically to test whether the shipment of the control samples between the
repositories and the IQAC affected sample integrity. There was no evidence that the control
sample post-thaw viabilities or recoveries were not equivalent (p<0.001 and p=0.005,
respectively), which suggests that the shipment of the control sample between the
repositories and the IQAC did not negatively affect the sample integrity (data not shown).
Control sample post-thaw QC data collected over two years are presented in Figure 3 for
each thawing location. One hundred percent of all the control sample vials exhibited post-
thaw viability values that passed the acceptance criteria with a consensus mean viability (+/
− SD) of 97.4% +/− 1.7%. As shown in Figure 3A, the mean control sample viability was
within the acceptance criteria at each thawing location (95.9 to 99.0%). There is no evidence
that the control sample post-thaw viabilities at the four thawing locations are not equivalent
(all p-values <0.001).
The control sample cell recovery results indicate that 99.0% of vials passed the acceptance
criteria with a consensus mean recovery (+/− SD) of 86.7% +/− 11.9%. The percentage of
the vials that passed the acceptance criteria ranged from 92.6 to 100% depending on the
thawing location (Figure 3B). The mean control sample cell recovery at each thawing
location was within the acceptance criteria and ranged from 78.6 to 97.5%. Although there
was statistical evidence that the recoveries at the four thawing locations were not equivalent,
99.0% of the control sample vials showed post-thaw recovery within acceptance criteria
(Figure 3B).
The mean thawing quarterly results were plotted for each liquid nitrogen freezer (Figure 4).
A regression analysis was performed to determine whether the integrity of the control
samples was maintained over time in storage. As shown in Figure 4A, the mean post-thaw
viability values from each repository freezer remained unchanged over the two-year period
of monitoring. There is no statistical evidence that the post-thaw viability values for each of
the repository freezers are trending downward over time (all p-values <0.001). As shown in
Figure 4B, the mean post-thaw cell recovery values from each repository freezer remained
within the acceptance criteria over the two-year period of monitoring. However, there is
statistical evidence that the post-thaw cell recovery values from repository 3 trended
downward overtime (p-value = 1.00, otherwise all p-values <0.001).
4.0 Discussion
In this study, we present results obtained from a PBMC QA program designed to assess
PBMC integrity upon initial isolation at the international CHAVI site-affiliated laboratories
(Stage 1), after cryopreservation, handling and shipment to the CHAVI repositories (Stage
2) and upon long-term storage in liquid nitrogen freezers at the CHAVI repositories (Stage
3). Acceptance criteria were set for each key QC indicator and corrective actions, including
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site visits and necessary retraining, were implemented in the event of QC failures. It is
important to note that the CHAVI PBMC QA program operated in site-affiliated laboratories
and repositories that followed GCLP, including the use of CHAVI Central SOPs, training
and competency assessments prior to initiating the study, and the monitoring and
maintenance of the facility and equipment.
The integrity of the PBMC upon isolation appeared high since the mean PBMC initial
viability, PBMC yield and processing time at each site-affiliated laboratory were within the
acceptance criteria (Table 1). 97.7% of PBMC preparations had initial viabilities of ≥95%,
87.7% had yields of 0.7 – 3.0 x 106 PBMC/mL blood, and 99.3% of the PBMC were frozen
within eight hours of blood collection. PBMC viability values were consistently high at five
site-affiliated laboratories, the PBMC yields were within the acceptance criteria at each site-
affiliated laboratory and, with the exception of one site, were similar across site-affiliated
laboratories and over time. One site-affiliated laboratory exhibited higher PBMC yields at
all times. Since this site-affiliated laboratory used the Vi-Cell instrument without RBC lysis
to count cells, counting of RBCs may have contributed to the high PBMC yield values.
Subsequent decreases in yield occurred after the site-affiliated laboratory began to verify
any out of criteria yield results obtained with the Vi-Cell automated counter, by using
hemacytometer counts.
Corrective action instituted by the site-affiliated laboratory managers when PBMC QC
values did not meet the acceptance criteria included observation and retraining of the PBMC
processing operators. Common recommendations included decreasing the force used and the
formation of bubbles during pipetting and cell resuspension and the verification of out of
criteria results. Additional recommendations for the improvement of PBMC yield included
ensuring that the centrifugation speeds and brake settings were correct; that the PBMC layer
was completely and cleanly harvested without excess plasma; and that the hemacytometer
and cover glass were clean and free of scratches. In the few instances where PBMC
processing times were greater than 8 hours, the root cause was usually a delay in the
transport of the blood specimens from the clinic to the site-affiliated laboratory, and
corrective actions were instituted to decrease this delay. This suggests that the continuous
monitoring of the PBMC QC coupled with observation and retraining, where necessary,
provided an important feedback mechanism to reach and maintain high initial PBMC
integrity.
Since many cell-mediated-immunity assays using cryopreserved PBMC are dependent on
the post-thaw PBMC viability (Cox et al., 2005; Kreher et al., 2003; Reimann et al., 2000;
Sleasman et al., 1997; Weinberg et al., 2000; Weinberg et al., 2009; Weinberg et al., 2010),
the results from the Stage 2 highlight how important it is to monitor post-thaw viability of
cryopreserved PBMC. Earlier studies suggested that short-term storage of PBMC in liquid
nitrogen at the site-affiliated laboratories and shipment in liquid nitrogen to the repositories
results in higher PBMC post-thaw viability and recovery in comparison to short-term
storage at −70°C and shipment on dry ice (Bull et al., 2007). Therefore, the decision was
made to use liquid nitrogen for short-term site-affiliated laboratory storage and for shipment
to the repositories. However, it should be noted that, in resource poor settings, careful
consideration must be given to the maintenance of reliable supplies of liquid nitrogen,
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including the establishment of on-site liquid nitrogen production facilities where necessary.
In fact, the two site-affiliated laboratories with the lowest PBMC post-thaw viability QC
values had a persistent problem maintaining adequate liquid nitrogen.
The sentinel control sample post-thaw QC results from the three CHAVI repositories and the
IQAC, which was utilized as a CHAVI-independent third party, were used to identify
potential problems in the long-term storage of PBMC specimens. The thawing of sentinel
control samples was used to monitor the freezer storage conditions without the need to thaw
CHAVI cryopreserved PBMCs, and it also provided a direct comparison between post-thaw
viability and recovery results obtained from the four thawing locations. This was especially
important since the central repositories thawed PBMC from the site-affiliated laboratories to
monitor the quality of the PBMC produced for CHAVI (Stage 2) and to determine the
competency of the site-affiliated laboratory operators to isolate PBMC.
Corrective action instituted by the site-affiliated laboratory managers when PBMC post-
thaw viability and cell recovery did not meet the acceptance criteria included observation
and retraining of the PBMC processing operators and those involved in PBMC shipments.
Additional training by the central repositories was also instituted at site-affiliated
laboratories 5, 6, and 7. The common recommendations for the improvement of initial
PBMC viability and yield also held for the improvement of PBMC post-thaw QC values.
These included ensuring that the residual medium remaining after the final wash prior to the
addition of the cryopreservation solution was adequately removed and that the chilled
cryopreservation solution was added drop-wise to the chilled cell suspension. A consistent
problem identified at site-affiliated laboratories 6 and 7 was a difficulty in maintaining
adequate supplies of liquid nitrogen, with possible failure to maintain the cryopreserved
PBMC specimens at cryogenic temperatures in liquid nitrogen vapor/transfer pans during
inventory procedures or preparation for shipment.
There was no evidence that the acute HIV+, established HIV+ and HIV negative cohort
PBMC initial viability, yield and processing time were not equivalent using the predefined
equivalence margins. A statistical analysis of the effect of HIV-status on PBMC post-thaw
viability and recovery was not performed because samples from established HIV-infected
participants were available for thawing only from one site-affiliated laboratory, and the
samples thawed from the other site-affiliated laboratories were almost exclusively from
HIV-negative participants. However, comparable post-thaw recoveries of viable PBMC
from HIV+ and HIV negative cohorts were obtained in two multicenter study (Kleeberger et
al., 1999; Weinberg et al., 2009; Aziz et al, 2013), supporting the validity of using either
cohort PBMC to monitor these QC indicators, as done in the studies described herein.
Ultimately, the quality-controlled CHAVI PBMC specimens were successfully utilized in
numerous immunogenicity studies, requiring viable and functional cells, by international
CHAVI end user laboratories. Supplementary Table S1 lists 21 selected publications within
2013, on functional immunogenicity studies performed using CHAVI PBMC, which were
processed, cryopreserved, shipped and stored as part of the CHAVI PBMC QA oversight
program described in this manuscript. Supplementary Figures S2 and S3 clearly depict the
detection of low frequency, functional antigen-specific T cells obtained from the thawed
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PBMC stored at CHAVI central repository 1, providing evidence that the integrity of the
CHAVI specimens, assessed by the CHAVI QA Program, was indeed maintained.
The quarterly Stage 3 results presented in Figure 4 suggest that the viability and recovery of
the cryopreserved PBMC stored in CHAVI repositories liquid nitrogen freezers were
maintained long-term. Our study has only examined the post-thaw viability and recovery of
the sentinel cryopreserved control samples over two years. Further studies are ongoing to
monitor these key quality indicators for control samples over longer lengths of storage time,
as described by other multicenter studies (Kleeberger et al., 1999).
The yearly costs of conducting the comprehensive CHAVI PBMC QA oversight program,
which included all QC activities at the site-affiliated laboratories, at the repositories and
IQAC for all stages described herein, were estimated to be approximately $3,000/year/site-
affiliated laboratory. This cost estimate was calculated in fiscal year 2013, and it is provided
to aid future consortia in the planning of similar comprehensive PBMC QA programs.
Each of the stages of the CHAVI PBMC QA oversight program monitored PBMC quality
indicators critical for the successful use of cryopreserved PBMC in cell-mediated-immunity
assays. The results suggest that it is more difficult to reach the post-thaw viability of ≥80%
acceptance criteria (Stage 2) than to achieve the acceptance criteria for PBMC initial
viability, yield, processing time (Stage 1) or for post-thaw recovery (Stage 2). In this sense,
the most cost-effective portion of the CHAVI PBMC QA Program has been the Stage 2 -
Cryopreserved PBMC viability and cell recovery after thawing at the repositories because it
effectively identified site-affiliated laboratories requiring additional training or resources.
The Stage 3 – Sentinel Program for long-term storage of cryopreserved PBMCs at the
repositories assured that PBMC integrity were maintained during storage and monitored the
comparability of PBMC thawing and counting at the repositories.
5.0 Conclusions
The CHAVI PBMC QA oversight program assessed the integrity of PBMC obtained from
multiple international sites at isolation and after subsequent cryopreservation, handling,
shipment, thaw and storage at the repositories. All of the nine site-affiliated laboratories
exhibited high PBMC QC performance for Stage 1 and isolated PBMC with high initial
viability, expected PBMC yields and processing times of ≤8 hours. The Stage 2 assessment
at the repositories resulted in the ability to identify site-affiliated laboratories that required
additional training or resources for the production of high quality cryopreserved PBMC
having a viability of greater than 80% upon thaw. The CHAVI PBMC QA oversight
program also assessed that stable conditions were monitored and maintained during long-
term storage at the repositories.
Overall, the CHAVI PBMC QA oversight program results highlight the relative importance
of each of its stages to the ultimate goal of preserving specimen integrity from collection to
long-term storage. The most crucial results were derived from Stage 2, where the quality of
PBMC was tested by thawing at the central repositories, although all parts of the program
contributed substantially to monitoring specimen integrity. To help the design of similar
future programs, we estimated that the cost per year required to support this program was
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approximately $3,000/year/site-affiliated laboratory. The CHAVI PBMC QA Program is
one of several parallel programs utilized by international HIV-network organizations to
control specimen integrity. Lessons learned from each of these programs may aid in the
design of a unified one in the future.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Design of the CHAVI PBMC QA Oversight Program
This schematic illustrates the shipment of PBMC from the site-affiliated laboratories to the
repositories and to end user laboratories and the stages of the CHAVI PBMC QA Oversight
Program: Stage 1 - PBMC Initial viability, yield, and processing time at the site-affiliated
laboratories; Stage 2 - Cryopreserved PBMC viability and cell recovery after thawing at the
repositories; Stage 3 - Sentinel Program for long-term storage of cryopreserved PBMCs at
the repositories.
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Fig. 2. Stage 2 - Cryopreserved PBMC Viability and Cell Recovery after Thawing at the
Repositories
The Day 1 PBMC post-thaw viability (Panel A) and total cell recovery (Panel B) QC results
from PBMC preparations collected over five years from each site-affiliated laboratory are
presented. The bars represent the raw data mean +/− 95% Confidence Interval (CI) for the
QC results (left axis). The circle markers on the line represent the percent of the PBMC
preparations from each site-affiliated laboratory that passed the acceptance criteria (right
axis). The asterisks in Panel A indicate that the viability results differed between site-
affiliated laboratories based on non-overlapping model-based 95% CI boundaries of the
means. The upper and lower limits of the acceptance criteria are indicated by the horizontal
dotted line(s) in each of the graphs. Acceptance criteria for PBMCs: post thaw viability
≥80%; post-thaw total cell recovery 55–120%.
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Fig. 3. Stage 3 - Sentinel Program for Long-Term Storage of Cryopreserved PBMCs at the
Repositories
The control sample post-thaw viability (Panel A) and Day 1 total cell recovery (Panel B)
QC results collected over two years from each thawing location are presented. The bars
represent the raw data mean +/− 95% CI for the viability results and the model-based mean
+/− 95% CI for the recovery results (left axis). The circle markers on the line represent the
percent of the control sample vials from each thaw site that passed the acceptance criteria
(right axis) Acceptance criteria for the control samples: post-thaw viability ≥92.9%; post-
thaw recovery 57.7–120.7%.
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Fig. 4. Stage 3 - Sentinel Program for Long-Term Storage of Cryopreserved PBMCs at the
Repositories: Analysis of Each Repository Freezer over Time
Post-thaw viability (Panel A) and Day 1 total cell recovery (Panel B) QC results from the
control sample vials stored in each repository freezer [Freezer A and B at the central
repository 1 (R1 A, R1 B); Freezer A at the central repository 2 (R2 A); and Freezer A at the
repository 3 (R3 A)] over two years are presented. The markers represent the raw data mean
+/− 95% CI for the QC results. The asterisk in Panel B indicates that, by regression analysis,
Freezer A at repository 3 control sample post-thaw recoveries changed over time (p=1.000).
The upper and lower limits of the Acceptance Criteria are indicated by the horizontal dotted
line(s) in each of the graphs. Acceptance criteria for the control samples: post-thaw viability
≥92.9%; post-thaw recovery 57.7–120.7%.
Sarzotti-Kelsoe et al. Page 19











































Sarzotti-Kelsoe et al. Page 20
Table 1
Stage 1- PBMC Initial viability, yield, and processing time at the site- affiliated laboratories






All site affiliated laboratories values 98.3 +/− 1.5 1.14 +/− 0.5 4:35 +/− 1:23
Acceptance criteria ≥ 95 0.7–3.0 ≤ 8:00
% of sites within acceptance criteria 100 100 100
% of total specimens within acceptance
criteria 97.7 87.7 99.3
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